Bibliography
- Miller J, Tarter TH. Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate. Clin Interv Aging 2009;4:251-8
- Roehrborn CG, McConnell JD. Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. In: Walsh PC, Retik AB, Vaughan ED Jr, Wein AJ, editors. Campbell's Urology. WB Saunders; Philadelphia, PA: 2002. p. 1297-330
- Oesterling JE. Benign prostatic hyperplasia: a review of its histogenesis and natural history. Prostate Suppl 1996;6:67-73
- Barry MJ. Epidemiology and natural history of benign prostatic hyperplasia. Urol Clin North Am 1990;17:495-507
- Issa MM, Fenter TC, Black L, An assessment of the diagnosed prevalence of diseases in men 50 years of age or older. Am J Manag Care 2006;12(Suppl 4):S83-9
- Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: benign prostatic hyperplasia. J Urol 2005;173(4):1256-61
- US Census Bureau. US interim projections by age, sex, race, and Hispanic origin. Available from: http://www.census.gov/ipc/www/usinterimproj/natrojtab02a.pdf [Accessed on 26 April 2011]
- Keam S, Scott L. Dutasteride: a review of its use in the management of prostate disorders. Drugs 2008;68(4):463-85
- Naslund MJ, Issa MM, Grogg AL, Clinical and economic outcomes in patients treated for enlarged prostate. Am J Manag Care 2006;12(Suppl 4):S111-16
- McConnell J, Reginald B, Walsh P, The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998;338(9):557-63
- Avodart [package insert]. GlaxoSmithKline; Research Triangle Park, NC: 2010
- Proscar [package insert]. Merck & Co, Inc; Whitehouse Station, NJ: 2010
- Boyle P, Roehrborn C, Harkaway R, 5-alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery. Eur Urol 2004;45(5):620-6
- Roehrborn C, Siami P, Barkin J, Prostatic hyperplasia: 4-year Results from the CombAT Study. Eur Urol 2010;57:123-31
- Verhamme KMC, Dieleman JP, Bluemink GS, Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: the Triumph Project. Eur Urol 2003;44:539-45
- Nichol M, Knight T, Wu J, Evaluating use patterns of and adherence to medications for benign prostatic hyperplasia. Urology 2009;181:2214-22
- Gruschkus S, Poston S, Eaddy M, Chaudhari S. Adherence to 5-alpha reductase inhibitor therapy for benign prostatic hyperplasia: clinical and economic outcomes. Pharm Ther 2012;37(8):464-70
- Thomson Reuters. MarketScan research databases. Thomson Reuters; Ann Arbor, Mich: 2009
- Disease staging: coded criteria. 5th edition. Ann Arbor, MI: Thomson Medstat; 2003
- Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
- Fenter TC, Naslund MJ, Shah MB The cost of treating the 10 most prevalent diseases in men 50 years of age or older. Am J Manag Care 2006;12(suppl 4):S90-98